Home
overview

With increasing applications in research to provide sensitive quantitative measurements of gene expression, including SNP genotyping, mutation detection and quantification, and gene dosage studies, quantitative polymerase chain reaction technology (qPCR) could soon be the standard for determining the genetic changes in response to a pharmacological agent. 

Topic Overview

  • Biomarkers clinic
  • Increasing through-put
  • Solid Phase Gene Expression
  • Data Management
  • Whole Genome Expression Profiling

 

With equipment improving all the time to offer high assay throughput and shorter assay times there has never been a better time to review existing technology, and how it can be applied to research & development in your organisation.


Unique in the market place, the inaugural SMi Quantitative Polymerase Chain Reaction (qPCR) & Transcriptional Profiling conference brings together industry leaders to discuss opportunities, advances in technology and time saving strategies.  The agenda is case study led, allowing delegates to benchmark their own research against that of their peers.


The qPCR and Transcriptional Profiling event is exclusively designed for the senior level practitioners from the world’s leading pharmaceutical and biotechnology companies.This exclusive event consists of world-class keynote addresses, panel discussions and case-study sessions on all aspects of qPCR and Transcriptional Profiling, Biostatistics, increasing through-put, microarrays, microRNA expression and an exclusive Biomarkers Clinic!


Don’t miss out on this unique opportunity to increase your throughput, decrease costs and time and make your qPCR really work for you.  Can your company afford not to attend SMi’s qPCR 2009 event?

 

Vice president, Executive, Director, Project manager, Researcher or Scientist in Pharmaceutical and Biotech companies in the following areas will benefit from SMi's qPCR & Transcriptional Profiling conference: 
  • Translational Research
  • Biomarkers
  • Bioinformatics
  • Genomics
  • Pharmacogenomics
  • Molecular Profiling
  • Clinical Development
  • qPCR
  • Gene Expression
  • Translational Science
  • Biochemistry
  • Genomics
  • Biostatistics
  • High Throughput Technologies
  • Data Management
  • Cell Biology

Delegates will benefit from:

  • A unique format of delegate interaction to encourage networking and benchmarking
  • Post event follow up offering all documentation from the meeting and re-booking discounts
  • A diverse programme, drawing experience from Pharma, Academia and Solution providers

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Ian Kavanagh

Ian Kavanagh, Senior Scientist, Thermo Fisher Scientific

9:10 PRECLINICAL AND CLINICAL BIOMARKER ANALYSIS OF THE CDK INHIBITOR PHA-793887 BY MICROARRAYS AND RT-QPCR

Antonella Isacchi

Antonella Isacchi, Director, Biology, Discovery Research Oncology, Nerviano Medical Science

 

  • Mechanism of action of PHA-793887: preclinical compound characterization by Microarrays
  • Identification by Microarrays and RT- QPCR of a gene signature modulated in vitro by  the inhibitor as a possible biomarker of activity
  • Analysis of the gene signature modulation in human xenograft tumors and mouse skin as a surrogate tissue
  • Analysis of the gene signature modulation in skin biopsies of patients from a Phase I study by RT-PCR
  • Microarray analysis of gene modulation in tumor biopsies from the same patients

9:50 CONSIDERATIONS FOR INCREASING THROUGHPUT IN QPCR RESEARCH

Ian Kavanagh

Ian Kavanagh, Senior Scientist, Thermo Fisher Scientific

  • With the ever-growing popularity in the use of QPCR there is increasing demand for higher throughput of reactions and faster protocol times
  • Developing a fast QPCR assay has many challenges; in particular, the improvement in speed should not come at a loss of assay performance
  • Discussion of the common steps within the workflow of a reaction
  • Discuss the ways in which these steps can be optimised to reduce the overall time of a QPCR protocol
  • Discuss choices that can be made in order to minimize the variation in the data that could be introduced throughout the protocol

10:30 Morning Coffee

11:00 CONVERGENT FUNCTIONAL GENOMICS OF OLIGODENDROCYTE DIFFERENTIATIAN IDENTIFIES MULTIPLE AUTOINHIBITORY SIGNALING CIRCUITS

Rob van Huijsduijnen

Rob van Huijsduijnen, head Molecular Neurobiology, Merck Serono International

  • From Functional Genomics to Drug Target
  • Focus on converging differentiation pathways to filter out relevant genes  Integration of Whole Genome Expression profiling, high-throughput qPCR
  • Gene knockdown, Pathway Analysis and use of selective inhibitors
  • 11:40 SOME PITFALLS OF RT-QPCR

    Chaminda Salgado

    Chaminda Salgado, Head of PCR Services, NDA Analytics

  • Overview of different detection chemistries, with pros and cons
  • Is the selected detection chemistry really telling you what the PCR is doing, how to tell, and what to do?
  • Reverse transcription chemistries and enzymes, and why this should be of concern for measuring transcription
  • Overview of instrument optical technologies, and what are they doing?
  • Analysis of the data, is vendor provided analysis appropriate for your target gene
  • 12:20 Networking Lunch

    13:50 DYNAMIC MODULARITY IN PROTEIN INTERACTION NETWORKS PREDICTS BREAST CANCER OUTCOME

    Ian Taylor

    Ian Taylor, CSO, DyNeMo Biosystems (Samuel Lunefeld Research Institute Mt Sinai Hospital)

  • Translate gene expression data into protein levels in protein 
  • Interaction networks
  • Use this data to examine differences in the interaction  
  • Network between breast cancer patients
  • Use that data to predict patient outcome
  • 14:30 TRANSCRIPTION CHANGES IN PERIPHERAL BLOOD CELLS

    Roman Artymyshyn

    Roman Artymyshyn, Principal Scientist, Synaptic Pharmaceutical

  • Transcription changes are measured in human peripheral blood using qPCR
  • A focused, hypothesis driven approach and small gene set was used
  • Changes in transcription patterns can be used to differentiate subject groups
  • Goal is to identify transcription patterns that will predict appropriate treatment and treatment outcome
  • 15:10 Afternoon Tea

    15:40 CAN MICROARRAYS BE USED TO PREVENT FOOD ALLERGIES?

    Victor Turcanu

    Victor Turcanu, Lecturer in Paediatric Allergy, King's College London

  • Food allergy prevalence in children from developed countries more than doubled over the last decades
  • Food avoidance (as a strategy to prevent food allergies) has failed to stem this ‘allergy epidemics’
  • New approaches such as dietary interventions are successful in experimental and natural models
  • RNA Microarrays could determine the gene signature of the phenotype responsible for the development of a food allergy
  • Based upon the food allergy gene signature, therapeutic interventions can be proposed in order to prevent food allergies
  • Application: the LEAP (Learning Early about Peanut Allergy interventional trial for preventing peanut allergy
  • 16:20 Chairman's Opening Remarks and Close of Day

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Victor Turcanu

    Victor Turcanu, Lecturer in Paediatric Allergy, King's College London

    9:10 METHOD FOR EXTRACTION, REVERSE TRANSCRIPTION AND PCR APPLICABLE TO SINGLE CELL ANALYSIS

    Neven Zoric

    Neven Zoric, manager & co- founder, Tataa biocenter

    9:50 MicroRNA EXPRESSION PROFILES IN ACUTE MYELOID LEUKAEMIAS

    Silvana  Debernardi

    Silvana Debernardi, Research Assistant, Institute of Cancer

  • Use of stem-loop real-time PCR to measure the expression of miRNAs in 100 AML patient samples
  • Correlation of miRNA expression with cytogenetic features of the AML samples
  • Correlation of miRNA expression with gene expression profile of the same set of samples
  • Comparison of miRNA measurement by real-time PCR and detection by high-throughput clonal sequencing in a subset of AML patients
  • 10:30 Morning Coffee

    11:00 SCORPIONS REAL-TIME SIGNALING AND ITS APPLICATIONS IN COMPANION DIAGNOSTICS

    Sabina Patel

    Sabina Patel, Product Development Scientist, DxS Ltd

  •  Design and development of assays
  •  Validation of diagnostic tests

  • 11:40 SENSITIVITY, SPEED AND MULTIPLEXING - NEW TECHNOLOGIES IN RT-PCR

    Annette Tietze

    Annette Tietze, Senior Global Product Manager qPCR, QIAGEN

  • Technologies to improve the sensitivity of real-time PCR
  • Faster cycling PCR strategies
  • Multiplex real-time PCR without optimization
  • 12:20 Networking Lunch

    13:50 GENOMIC INTEGRATION FOR LONG-TERM GENE EXPRESSION USING

    Carsten Rudolph

    Carsten Rudolph, Professor, klinikum der Universitat Munchen

  • Magnetic drug targeting to the lungs
  • Targeted nanoparticles for aerosol gene delivery
  •  Using mRNA for pulmonary gene delivery
  • 14:30 BIOMARKERS TO CLINIC: A SYSTEM TO BANISH THE CURSE OF TOO MANY GENES AND TOO FEW SAMPLES

    Jim White

    Jim White, Europen Technical Manager, BioTrove Inc

  • The BioTrove OpenArrayTM NT Cycler system extends the reach of genomic discovery, validation and quantification processes by means of a unique  parallel array format
  • Using proven solution-based qPCR chemistries the system delivers outstanding analytical performance with medium throughput, with an ideal sample-feature ratio
  • Driving discoveries in gene signatures, quantitative trait loci, bridging the gaps in validation in toxicogenomics and pharmacogenomics towards translational medicine
  • 15:10 Afternoon Tea

    15:40 qPCR FOR IN VIVO QUANTIFICATION OF OLIGONUCLEOTIDE INDUCED ONCOGENE INHIBITION

    Claude Paul Malvy

    Claude Paul Malvy, Director, Universite Paris Sud

  •  The selected oligonucleotides allow both the in vivo inhibition of tumour growth and down regulation of the fusion oncogene at the mRNA level
  • RT PCR allows the identification in gel electrophoresis of the targeted mRNA
  • qPCR is therefore essential for the in vitro selection of the best oligonucleotides and for the confirmation that their antitumor activity in vivo is related to the targeted oncogene inhibition
  • 16:20 Chairman's Closing Remarks and Close of Conference

    +

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.